Table 3. Avoidance of exposure: characteristics and results of studies published between 2004 and 2010
First author [ref.]CountryAgentStudy designDuration of FU monthsSymptom recovery n/NRecovery of NSBHR n/N
Brant [34]UKEnzymesWorkforce-based survey of 35 out of 45 cases37 (4–39)5/35NA
Klusackova [35]Czech RepublicVariousLongitudinal FU of 37 cases (selection not stated) Clinic-based study78 (12–216)5/371/19
Labrecque [36]CanadaIsocyanatesRetrospective cohort study of compensated subjects (89 randomly selected subjects)∼24 for all subjects4/7910/79
Park [38]KoreaReactive dyesLongitudinal FU of 26 cases (selection not stated) Clinic-based studySecond visit: 104±22 (n=19)NA11/16
Park [37]KoreaReactive dyesLongitudinal FU of 11 cases (selection not stated) Clinic-based study164±280/113/11
Pisati [39]ItalyIsocyanatesLongitudinal FU of 53 cases (selection of 25 patients rechallenged with TDI) Clinic-based study58±7 (46–73)10/2512/25
Yacoub [40]CanadaVariousRetrospective cohort study of 40 compensated subjects44±346/4010/40
Munoz [41]SpainPersulfate saltsProspective longitudinal FU of 10 out of 11 cases Clinic-based study63±19 (39–101)2/75/7
Pooled estimates#32/234, 15.5% (8.3–27.1%)52/197, 32.8% (16.8–54.3%)
  • Data for individual studies are presented as mean (range), mean±sd or mean±sd (range), unless otherwise stated. Pooled estimates are presented as n/N with % (95% CI). FU: follow-up; NSBHR: nonspecific bronchial hyperresponsiveness; NA: not available; TDI: toluene diisocyanate. #: pooled estimates based on a random-effect model; : the rate of symptom recovery was 19.2% (28 out of 155 subjects; 95% CI 11.2–30.9%) after exclusion of the study by Labrecque et al. [36], which used more stringent criteria of “clinical remission” defined by the absence of symptoms, NSBHR and medication.